So-called monoclonal antibodies could help treat patients, protect at-risk groups, and also improve vaccines.
When President Trump announced an emergency use authorization for convalescent plasma as a “historic” and game-changing treatment for the coronavirus last month, experts were baffled. Although plasma donations from recovered patients have been used to speed recoveries for over a century and may help patients in early stages of Covid-19, there’s not enough research yet on how well this approach works and which antibodies best battle this virus. Now, however, there are preliminary results on a different but related treatment that could help coronavirus patients and solve some of those issues. And the administration hasn’t said much about it. It’s called monoclonal antibodies.
Not all antibodies a body produces in response to this coronavirus are created equal. Some are better at battling SARS-CoV-2 than others. A recovered patient might have a low number of antibodies, but if the antibodies they do have are all really good at neutralizing the virus, then plasma from that patient will be more effective. Another patient could have a high number of antibodies, but none of the antibodies are particularly good against this coronavirus and so they fare worse. Convalescent plasma as a treatment, therefore, is “a little bit of a crude method,” said Rogier Sandiers, a professor of virology at the University of Amsterdam’s Faculty of Medicine. You need large quantities of plasma from recovered patients, and “you have to be lucky with the plasma you get. If there’s no neutralizing antibodies in the plasma at hand, then it’s not going to be very effective.”
But what if the best, most effective antibodies could be designed in a lab and then mass-produced? Read more at The New Republic.
Categories: Freelance Articles